Enlivex Ltd.

ENLV Healthcare Biotechnology

In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.21 0.01 −4.55%
Market cap
$4.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
193.24 6.84 5.57 7.92 18.32 8.72 2.75 9.09 13.09 5.46
Net Debt/EBITDA
118.29 1.51 0.96 1.84 4.20 3.83 1.57 1.89 4.31 0.62
Debt/Equity
0.00 0.01 0.00 0.07 0.06 0.01 0.03 0.00 0.00 0.00
ROE
126.17% (55.95%) (66.88%) (43.78%) (24.01%) (50.56%) (91.71%) (56.96%) (38.50%) (120.33%)
ROA
104.94% (46.54%) (55.65%) (38.16%) (21.35%) (40.83%) (65.64%) (47.64%) (31.93%) (102.88%)
ROIC
(4.78%) (2,533.16%) (664.68%) (149.41%) (191.41%) 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
71.23% (65.80%) (99.40%) (55.87%) (17.17%) (33.56%) (84.62%) (49.85%) (36.57%) (184.56%)
Average Days of Receivables
— — — — — — 0.00 0.00 0.00 0.00
Free Cash Flow per Share
(3.44) (9.45) (19.07) (26.14) (16.09) (13.69) (12.53) (15.47) (10.65) (582.86)
Book value per Share
634.85 17.24 24.28 46.33 71.38 40.40 19.56 41.46 37.17 327.03
Free Cash Flow
(10.48) (12.93) (23.63) (32.07) (19.17) (12.03) (7.23) (3.62) (2.43) (15.50)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026